Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by modulexon Apr 19, 2021 1:56pm
200 Views
Post# 33022824

LET RIDE THIS STOCK A BIT MORE : INSIDERS BUYS

LET RIDE THIS STOCK A BIT MORE : INSIDERS BUYSFiling Date Transaction Date Insider Name Ownership Type Securities Nature of transaction Volume or Value Price Cameron Groome acquired 10,000 shares at $0.60 on April 15. Cameron Groome acquired 30,000 shares at $0.49 USD - sama date Martin Marino acquired 35,000 shares at $0.62 on April 13. Martin Marino acquired 65,000 at $0.616 - same date. Someone would be foolish here to sell below $1.00, in my view.
<< Previous
Bullboard Posts
Next >>